{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T18:01:35Z","timestamp":1774807295734,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.urolonc.2021.01.013","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T20:58:19Z","timestamp":1614286699000},"page":"442-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Adam S.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Delacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2021.01.013_bib0001","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"5.5","key":"10.1016\/j.urolonc.2021.01.013_bib0002","first-page":"591","article-title":"NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer","volume":"17","author":"Flaig","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.urolonc.2021.01.013_bib0003","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil\/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG\/RTOG 0712-A Randomized Phase II Trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncr.23137","article-title":"Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience","volume":"112","author":"Perdona","year":"2008","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.urolonc.2021.01.013_bib0006","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"Rodel","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.01.013_bib0007","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.urolonc.2009.01.031","article-title":"Updated results of bladder-sparing trimodality approach for invasive bladder cancer","volume":"28","author":"Zapatero","year":"2010","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0008","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-5347(17)38667-6","article-title":"Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study","volume":"142","author":"Wood","year":"1989","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2021.01.013_bib0009","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2016.10.061","article-title":"Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","article-title":"A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study","volume":"178","author":"Fradet","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","article-title":"Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy","volume":"188","author":"Grossman","year":"2012","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.01.013_bib0012","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.01.013_bib0013","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"Naito","year":"2016","journal-title":"Eur Urol"},{"issue":"1068","key":"10.1016\/j.urolonc.2021.01.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160296","article-title":"Fiducial marker guided prostate radiotherapy: a review","volume":"89","author":"O'Neill","year":"2016","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.01.013_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41416-018-0201-z","article-title":"Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?","volume":"119","author":"Thompson","year":"2018","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0016","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.prro.2013.07.008","article-title":"Image guided radiation therapy for bladder cancer: assessment of bladder motion using implanted fiducial markers","volume":"4","author":"Biancia","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.01.013_bib0017","doi-asserted-by":"crossref","first-page":"e89754","DOI":"10.1371\/journal.pone.0089754","article-title":"Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes","volume":"9","author":"Garcia","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.radonc.2007.08.011","article-title":"Fiducial markers in external beam radiotherapy for bladder cancer","volume":"85","author":"Lalondrelle","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2021.01.013_bib0019","unstructured":"https:\/\/www.spaceoar.com\/about\/traceit\/SHwU."},{"issue":"20","key":"10.1016\/j.urolonc.2021.01.013_bib0020","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0021","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.urolonc.2021.01.013_bib0022","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bju.14045","article-title":"Bladder cancer: diagnosis and management of bladder cancer","volume":"120","year":"2017","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2021.01.013_bib0023","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/bju.12291","article-title":"Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges","volume":"112","author":"Payne","year":"2013","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2021.01.013_bib0024","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.urolonc.2012.01.014","article-title":"Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients","volume":"31","author":"Koga","year":"2013","journal-title":"Urol Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2021.01.013_bib0025","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"Rodel","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euo.2019.09.008","article-title":"A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients","volume":"3","author":"Russell","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"Supplement 4","key":"10.1016\/j.urolonc.2021.01.013_bib0027","first-page":"e1027","article-title":"Role of routine biopsy after radiation-based therapy for muscle invasive bladder cancer","volume":"201","author":"Kool R","year":"2019","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1016\/j.urolonc.2021.01.013_bib0028","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1464-410X.2010.09696.x","article-title":"Transurethral resection of bladder tumour complicated by perforation requiring open surgical repair - clinical characteristics and oncological outcomes","volume":"107","author":"Golan","year":"2011","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.urolonc.2021.01.013_bib0029","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1089\/end.2017.0328","article-title":"Bipolar Transurethral Resection of Bladder Tumor Provides Better Tissue for Histopathology But Has No Superior Efficacy and Safety: A Randomized Controlled Trial","volume":"32","author":"Murugavaithianathan","year":"2018","journal-title":"J Endourol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.01.013_bib0030","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2013.12.004","article-title":"Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial","volume":"191","author":"Venkatramani","year":"2014","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.01.013_bib0031","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0090-4295(01)01219-5","article-title":"Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder","volume":"58","author":"Zietman","year":"2001","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2021.01.013_bib0032","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ijrobp.2007.08.007","article-title":"Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy","volume":"70","author":"Weiss","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.urolonc.2021.01.013_bib0033","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.urolonc.2006.09.015","article-title":"Long-term outcome of radiation-based conservation therapy for invasive bladder cancer","volume":"25","author":"Chung","year":"2007","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0034","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","article-title":"Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer","volume":"199","author":"Sanchez","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.01.013_bib0036","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2021.01.013_bib0037","doi-asserted-by":"crossref","first-page":"952","DOI":"10.6004\/jnccn.2013.0116","article-title":"Trimodality bladder preservation therapy for muscle-invasive bladder cancer","volume":"11","author":"Chen","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.urolonc.2021.01.013_bib0038","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.01.013_bib0039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0022-5347(01)63018-0","article-title":"Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure","volume":"160","author":"Bochner","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.01.013_bib0040","series-title":"Complications and survival outcomes of salvage cystectomy after trimodality therapy 19th Annual Meeting of the Society of Urologic Oncology","year":"2018"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:53Z","timestamp":1761042353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1078143921000120"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}